Lymphocyte-sparing radiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a special type of radiation therapy that aims to spare your immune cells (lymphocytes) while treating esophageal cancer. It may help patients with locally advanced esophageal squamous cell carcinoma who are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of esophageal squamous cell carcinoma.
- Your cancer is locally advanced (has spread to nearby tissues or lymph nodes, but not to distant organs).
- You are between 18 and 80 years old.
- Your Karnofsky Performance Status (a measure of daily function) is 80 or higher, meaning you can carry on normal activity with little effort.
- You are willing to receive systemic drug treatment as part of your care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
Hear when a new Esophageal Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.